Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance (ACCESS II)

This study has been completed.
Sponsor:
Information provided by:
Galderma
ClinicalTrials.gov Identifier:
NCT00687908
First received: May 28, 2008
Last updated: September 30, 2010
Last verified: September 2010
Results First Received: July 16, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Acne
Interventions: Drug: Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel
Drug: Vehicle Gel

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment period: 12 NOV 2008 to 09 FEB 2009 in thirty-four centers (29 in the USA and 5 in Canada) public or private practices. Twenty-four USA centers and four Candadian centers used a central IRB, and the others used a local IRB.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Adapalene-BPO Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel
Vehicle Vehicle Gel

Participant Flow:   Overall Study
    Adapalene-BPO   Vehicle
STARTED   123   120 
COMPLETED   105   78 
NOT COMPLETED   18   42 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Adapalene-BPO Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel
Vehicle Vehicle Gel
Total Total of all reporting groups

Baseline Measures
   Adapalene-BPO   Vehicle   Total 
Overall Participants Analyzed 
[Units: Participants]
 123   120   243 
Age 
[Units: Participants]
     
<=18 years   76   84   160 
Between 18 and 65 years   47   36   83 
>=65 years   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 19.1  (5.89)   18.2  (5.23)   18.6  (5.58) 
Gender 
[Units: Participants]
     
Female   58   53   111 
Male   65   67   132 
Region of Enrollment 
[Units: Participants]
     
United States   84   79   163 
Puerto Rico   13   13   26 
Canada   26   28   54 


  Outcome Measures
  Hide All Outcome Measures

1.  Primary:   Maintenance Success for Total Lesions at Week 24   [ Time Frame: Week 24 ]

Measure Type Primary
Measure Title Maintenance Success for Total Lesions at Week 24
Measure Description Maintenance success for total lesions at Week 24 is defined as the percentage of subjects maintaining at least 50 percent of the improvement obtained with prior combination therapy, in terms of total lesion counts.
Time Frame Week 24  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT - Worst-case (Any missing data at Week 24 is considered as a failure)

Reporting Groups
  Description
Adapalene-BPO Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel
Vehicle Vehicle Gel

Measured Values
   Adapalene-BPO   Vehicle 
Participants Analyzed 
[Units: Participants]
 123   120 
Maintenance Success for Total Lesions at Week 24 
[Units: Percent of subjects]
 78.9   45.8 

No statistical analysis provided for Maintenance Success for Total Lesions at Week 24



2.  Secondary:   Maintenance Success for Inflamatory Lesions at Week 24   [ Time Frame: Week 24 ]

Measure Type Secondary
Measure Title Maintenance Success for Inflamatory Lesions at Week 24
Measure Description Maintenance success for inflamatory lesions at Week 24 is defined as the percentage of subjects maintaining at least 50 percent of the improvement obtained with prior combination therapy, in terms of inflamatory lesion counts.
Time Frame Week 24  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT - Worst-case (Any missing data at each visit is considered as a failure, except where maintenance rate of both previous and following visits are success)

Reporting Groups
  Description
Adapalene-BPO Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel
Vehicle Vehicle Gel

Measured Values
   Adapalene-BPO   Vehicle 
Participants Analyzed 
[Units: Participants]
 123   120 
Maintenance Success for Inflamatory Lesions at Week 24 
[Units: Percent of subjects]
 78   48.3 

No statistical analysis provided for Maintenance Success for Inflamatory Lesions at Week 24



3.  Secondary:   Maintenance Success for Non-inflammatory Lesions at Week 24   [ Time Frame: Week 24 ]

Measure Type Secondary
Measure Title Maintenance Success for Non-inflammatory Lesions at Week 24
Measure Description Maintenance success for non-inflamatory lesions at Week 24 is defined as the percentage of subjects maintaining at least 50 percent of the improvement obtained with prior combination therapy, in terms of non-inflamatory lesion counts.
Time Frame Week 24  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT - Worst-case (Any missing data at each visit is considered as a failure, except where maintenance rate of both previous and following visits are success)

Reporting Groups
  Description
Adapalene-BPO Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel
Vehicle Vehicle Gel

Measured Values
   Adapalene-BPO   Vehicle 
Participants Analyzed 
[Units: Participants]
 123   120 
Maintenance Success for Non-inflammatory Lesions at Week 24 
[Units: Percent of subjects]
 78   43.3 

No statistical analysis provided for Maintenance Success for Non-inflammatory Lesions at Week 24



4.  Secondary:   Investigator Global Assessment (IGA) Maintenance Success at Week 24   [ Time Frame: Baseline, Week 24 ]

Measure Type Secondary
Measure Title Investigator Global Assessment (IGA) Maintenance Success at Week 24
Measure Description

IGA maintenance success is defined as the percentage of subjects with IGA grade inferior or equal to Baseline IGA grade.

IGA grade:

0 Clear:Residual hyperpigmentation & erythema may be present

  1. Almost Clear:A few scattered comedones & a few small papules.
  2. Mild:Some comedones & some papules and pustules. No nodules present
  3. Moderate:Many comedones, papules & pustules. One nodule may be present
  4. Severe:Covered with comedones, numerous papules & pustules & few nodules & cysts may be present
  5. Very severe:Highly inflammatory acne covering the face; with nodules & cysts present
Time Frame Baseline, Week 24  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT - Worst-case (Any missing data at each visit is considered as a failure, except where maintenance rate of both previous and following visits are success)

Reporting Groups
  Description
Adapalene-BPO Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel
Vehicle Vehicle Gel

Measured Values
   Adapalene-BPO   Vehicle 
Participants Analyzed 
[Units: Participants]
 123   120 
Investigator Global Assessment (IGA) Maintenance Success at Week 24 
[Units: Percent of subjects]
 70.7   34.2 

No statistical analysis provided for Investigator Global Assessment (IGA) Maintenance Success at Week 24



5.  Secondary:   Percent of Subjects With Adverse Events   [ Time Frame: Up to 24 weeks ]

Measure Type Secondary
Measure Title Percent of Subjects With Adverse Events
Measure Description All participants with events were measured for that particular Outcome Measure and not only the events with a frequency threshold above 2 percent
Time Frame Up to 24 weeks  
Safety Issue Yes  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Adapalene-BPO Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel
Vehicle Vehicle Gel

Measured Values
   Adapalene-BPO   Vehicle 
Participants Analyzed 
[Units: Participants]
 123   120 
Percent of Subjects With Adverse Events 
[Units: Percent of subjects]
 41.5   29.2 

No statistical analysis provided for Percent of Subjects With Adverse Events




  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information